{"entity":{"id":"nct05547061","kind":"trial","name":"A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy","aka":[],"tldr":"A phase 1/2 trial of Lu-177-DGUL in prostate cancer, run by Cellbion Co., Ltd., active and no longer recruiting.","summary":"A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy is a phase 1/2 interventional study registered as NCT05547061 by Cellbion Co., Ltd., with 91 participants enrolled, started 2021-04-12 and due to reach its primary completion in 2024-12-31. Interventions recorded: Lu-177-DGUL and Ga-68-NGUL.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05547061","url":"https://clinicaltrials.gov/study/NCT05547061"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate","prostate-mcrpc"],"sections":[],"technologies":["lu177-radioligand-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05547061","phase":"1/2","setting":"A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy","sponsor":"Cellbion Co., Ltd.","participation":[{"nct":"NCT05547061","source":"https://clinicaltrials.gov/study/NCT05547061","fetchedAt":"2026-10-07T16:53:45.224Z","studySha256":"edb8880ae040b861dace52483a30ab065e0f1c62d7ac3b73683a565933947014","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2024-12-11","leadSponsor":"Cellbion Co., Ltd.","collaboratorCount":0,"minimumAge":"19 Years","sex":"MALE","healthyVolunteers":true,"hasEligibility":true,"enrolment":91,"enrolmentType":"ACTUAL","siteCount":4,"recruitingSiteCount":0,"countries":["South Korea"]}],"started":"2021-04-12","startedType":"actual","enrolled":91,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05547061/","neighbours":{"cancer":[{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"technology":[{"id":"lu177-radioligand-therapy","kind":"technology","name":"Lutetium-177 radioligand therapy","route":"/technologies/lu177-radioligand-therapy/"}]}}